Core Viewpoint - The company, Shanghai Youningwei Biotechnology Co., Ltd., has approved the use of idle funds for cash management, allowing the investment of up to RMB 300 million in idle raised funds and RMB 1.5 billion in self-owned funds for a period of 12 months starting from March 9, 2025 [1]. Group 1: Cash Management Details - The company plans to invest in structured deposits and low-risk non-principal guaranteed financial products, which are categorized as low-risk investment types [1]. - The expected annualized returns for various structured deposits range from 0.59% to 2.8186% [5]. - The total amount of raised funds (including oversubscribed funds) used for structured deposits as of July 4, 2025, is RMB 195 million, while the amount of self-owned funds used is RMB 850 million [2]. Group 2: Investment Breakdown - Specific structured deposit investments include: - RMB 2 million with Industrial Bank, expected return of 2.10% [5]. - RMB 3 million with China Merchants Bank, expected return of 2.00%-2.30% [5]. - RMB 4 million with Bank of China, expected return of 0.5900% or 2.8186% [5]. - RMB 10 million with Industrial Bank, expected return of 1.20% or 2.15% [5]. - The company has also engaged with various banks for structured deposits, including Ping An Bank and Shanghai Pudong Development Bank, with amounts ranging from RMB 1 million to RMB 25 million [2][3][4]. Group 3: Risk Management and Operational Impact - The company emphasizes that cash management will not affect its normal operations and aims to enhance fund utilization efficiency while ensuring the safety of the principal [1]. - Risk control measures include maintaining close contact with financial institutions and conducting audits to verify the cash management fund usage [1].